$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2012 Q2 Form 10-Q Financial Statement

#000117891312001000 Filed on April 04, 2012

Income Statement

Concept	2012 Q2	2012 Q1	2011 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$290.0K	$230.0K	$310.0K
YoY Change	-17.14%	-25.81%	47.62%
% of Gross Profit
Research & Development	$249.8K	$710.6K	$341.3K
YoY Change	3.48%	108.2%	89.63%
% of Gross Profit
Depreciation & Amortization	$10.00K	$0.00	$10.00K
YoY Change		-100.0%	0.0%
% of Gross Profit
Operating Expenses	$249.8K	$710.6K	$341.3K
YoY Change	3.48%	108.2%	-12.48%
Operating Profit	-$540.4K	-$940.4K	-$647.2K
YoY Change	-8.63%	45.29%
Interest Expense	-$10.00K	$0.00	$0.00
YoY Change	-100.95%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$550.4K	-$985.4K	-$642.8K
YoY Change	-220.33%	53.3%	64.82%
Income Tax
% Of Pretax Income
Net Earnings	-$550.4K	-$985.4K	-$642.8K
YoY Change	-220.33%	53.3%	64.82%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$93.70K	-$169.2K	-$122.4K
COMMON SHARES
Basic Shares Outstanding	70.32M	70.19M
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q2	2012 Q1	2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.160M	$3.000M	$3.710M
YoY Change	-50.23%	-19.14%	75.0%
Cash & Equivalents	$1.300M	$1.824M	$1.932M
Short-Term Investments	$860.0K	$1.180M	$1.780M
Other Short-Term Assets	$40.00K	$30.00K	$40.00K
YoY Change	33.33%	-25.0%	-66.67%
Inventory
Prepaid Expenses	$21.04K	$12.81K
Receivables	$135.4K	$46.67K	$90.00K
Other Receivables	$127.1K	$28.05K	$0.00
Total Short-Term Assets	$2.458M	$3.108M	$3.840M
YoY Change	-50.13%	-19.06%	56.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.121K	$7.792K	$30.00K
YoY Change	-89.4%	-74.03%	-50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.00K	$10.00K	$30.00K
YoY Change	0.0%	-66.67%	200.0%
Other Assets	$0.00	$20.00K
YoY Change
Total Long-Term Assets	$15.79K	$34.31K	$50.00K
YoY Change	-47.37%	-31.39%	-28.57%
TOTAL ASSETS
Total Short-Term Assets	$2.458M	$3.108M	$3.840M
Total Long-Term Assets	$15.79K	$34.31K	$50.00K
Total Assets	$2.474M	$3.143M	$3.890M
YoY Change	-50.12%	-19.21%	53.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$310.0K	$530.0K	$520.0K
YoY Change	0.0%	1.92%	116.67%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$355.9K	$582.2K	$570.0K
YoY Change	-1.15%	2.13%	103.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$150.0K	$160.0K	$160.0K
YoY Change	-6.25%	0.0%	6.67%
Total Long-Term Liabilities	$146.8K	$162.0K	$160.0K
YoY Change	-8.23%	1.27%	6.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$355.9K	$582.2K	$570.0K
Total Long-Term Liabilities	$146.8K	$162.0K	$160.0K
Total Liabilities	$502.7K	$744.1K	$730.0K
YoY Change	-3.33%	1.94%	69.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.56M	-$16.01M
YoY Change
Common Stock	$18.52M	$18.41M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.972M	$2.398M	$3.160M
YoY Change
Total Liabilities & Shareholders Equity	$2.474M	$3.143M	$3.890M
YoY Change	-50.12%	-19.21%	53.75%

Cashflow Statement

Concept	2012 Q2	2012 Q1	2011 Q1
OPERATING ACTIVITIES
Net Income	-$550.4K	-$985.4K	-$642.8K
YoY Change	-220.33%	53.3%	64.82%
Depreciation, Depletion And Amortization	$10.00K	$0.00	$10.00K
YoY Change		-100.0%	0.0%
Cash From Operating Activities	-$880.0K	-$600.0K	-$200.0K
YoY Change	51.72%	200.0%	-52.38%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$340.0K	$960.0K	-$1.780M
YoY Change	-3500.0%	-153.93%
Cash From Investing Activities	$340.0K	$960.0K	-$1.780M
YoY Change	-3500.0%	-153.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	2.810M
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-880.0K	-600.0K	-200.0K
Cash From Investing Activities	340.0K	960.0K	-1.780M
Cash From Financing Activities	0.000	0.000	2.810M
Net Change In Cash	-540.0K	360.0K	830.0K
YoY Change	5300.0%	-56.63%	-297.62%
FREE CASH FLOW
Cash From Operating Activities	-$880.0K	-$600.0K	-$200.0K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$880.0K	-$600.0K	-$200.0K
YoY Change	51.72%	200.0%	-52.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	16900	USD
	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	19777	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Period End Date DocumentPeriodEndDate	2012-02-29
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001176309
CY2012Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70320583
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	615882	USD
CY2011	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	26733	USD
CY2011	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3782	USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature	108000	USD
	ormp	Imputed Interest Expense ImputedInterestExpense		USD
	ormp	Imputed Interest Expense ImputedInterestExpense	1891	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	ormp	Imputed Interest Expense ImputedInterestExpense	23559	USD
	ormp	Issuance Of Stock And Warrants To Be Issued For Services Or Claims IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims	30435	USD
	ormp	Issuance Of Stock And Warrants To Be Issued For Services Or Claims IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims		USD
	ormp	Issuance Of Stock And Warrants To Be Issued For Services Or Claims IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims	30435	USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances	6061	USD
	ormp	Receipts On Account Of Shares And Warrants ReceiptsOnAccountOfSharesAndWarrants	6061	USD
	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	821337	USD
CY2011	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	227569	USD
	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	24900	USD
	ormp	Stock Issued During Period Value Services Rendered StockIssuedDuringPeriodValueServicesRendered	30435	USD
	ormp	Weighted Average Number Of Basic And Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare	70140610
	ormp	Weighted Average Number Of Basic And Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare	60344880
CY2012Q1	ormp	Weighted Average Number Of Basic And Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare	70176638
CY2011Q1	ormp	Weighted Average Number Of Basic And Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare	62804799
CY2011Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	375538	USD
CY2012Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	534907	USD
CY2011Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2012Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2011Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	542891	USD
CY2012Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	46668	USD
CY2011Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	18201111	USD
CY2012Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	18339399	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18991	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3554921	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	502593	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	66136	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2011Q3	us-gaap	Assets Assets	4325937	USD
CY2012Q1	us-gaap	Assets Assets	3142588	USD
CY2011Q3	us-gaap	Assets Current AssetsCurrent	4284082	USD
CY2012Q1	us-gaap	Assets Current AssetsCurrent	3108283	USD
CY2002Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
CY2010Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1199638	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1513365	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1824141	USD
CY2011Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1931761	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	310776	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	732123	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1824141	USD
CY2011Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2012Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2011Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70104583
CY2012Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70187583
CY2011Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70104583
CY2012Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70187583
CY2011Q3	us-gaap	Common Stock Value CommonStockValue	70104	USD
CY2012Q1	us-gaap	Common Stock Value CommonStockValue	70187	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16	USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty	18991	USD
CY2011Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1801400	USD
CY2012Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	838738	USD
	us-gaap	Depreciation Depreciation	11713	USD
	us-gaap	Depreciation Depreciation	15122	USD
	us-gaap	Depreciation Depreciation	117820	USD
CY2012Q1	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	432	USD
CY2011Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	18502	USD
CY2012Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.02
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2963	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	570	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-295	USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2012Q1	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2011Q1	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	511605	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	621016	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	229704	USD
CY2011Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	305887	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7469988	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1463894	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1245575	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-985375	USD
CY2011Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-642791	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15860635	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2011Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	150558	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	140867	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	107249	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	534907	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	138054	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	1307	USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations		USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	23982	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30802	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29124	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	87140	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	7509	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-8	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	16000	USD
CY2011Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	10186	USD
CY2012Q1	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	9412	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	24900	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	119800	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1072996	USD
CY2011Q3	us-gaap	Liabilities Liabilities	602021	USD
CY2012Q1	us-gaap	Liabilities Liabilities	744145	USD
CY2011Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4325937	USD
CY2012Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3142588	USD
CY2011Q3	us-gaap	Liabilities Current LiabilitiesCurrent	441292	USD
CY2012Q1	us-gaap	Liabilities Current LiabilitiesCurrent	582159	USD
CY2011Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	160729	USD
CY2012Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	162036	USD
CY2011Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	138054	USD
CY2012Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	138054	USD
CY2011Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	384565	USD
CY2012Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	341454	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3106000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12002997	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1405536	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1678475	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-540131	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1094760	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-695402	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9638725	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12986038	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-1561245	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1463894	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2012Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2011Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	434876	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	43111	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Net Income Loss NetIncomeLoss	-1245575	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-985375	USD
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	-642791	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16011193	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1406268	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1248832	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-940351	USD
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-647215	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16651376	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	29043	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	6788	USD
CY2012Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9487	USD
CY2011Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3432	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	210300	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	14528	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	10045	USD
CY2012Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7574	USD
CY2011Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7856	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	208560	USD
CY2011Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	24191	USD
CY2012Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	28045	USD
CY2012Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	43111	USD
CY2011Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	240523	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	3597	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities		USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	17890	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2129	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1475	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125612	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	-961262	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1677000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4467120	USD
CY2011Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	22675	USD
CY2012Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7792	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
CY2012Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	23982	USD
CY2011Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1670	USD
CY2012Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12805	USD
CY2011Q3	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	14293	USD
CY2012Q1	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	17101	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3106000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11655693	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	120000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	66243	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	3628000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	450000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments		USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	450000	USD
CY2011Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17376	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	120000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	894663	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	627816	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	710647	USD
CY2011Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	341328	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8746512	USD
CY2011Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2012Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2011Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14547299	USD
CY2012Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16011193	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	83036	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	335797	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4783165	USD
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	53700	USD
CY2010Q3	us-gaap	Stockholders Equity StockholdersEquity	830272	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	3723916	USD
CY2012Q1	us-gaap	Stockholders Equity StockholdersEquity	2398393	USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	1753	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	275000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7907781	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3694212	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	434876	USD

Files In Submission

Name	View Source	Status
0001178913-12-001000-index-headers.html	Edgar Link	pending
0001178913-12-001000-index.html	Edgar Link	pending
0001178913-12-001000.txt	Edgar Link	pending
0001178913-12-001000-xbrl.zip	Edgar Link	pending
exhibit_31-1.htm	Edgar Link	pending
exhibit_31-2.htm	Edgar Link	pending
exhibit_32-1.htm	Edgar Link	pending
exhibit_32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
ormp-20120229.xml	Edgar Link	completed
ormp-20120229.xsd	Edgar Link	pending
ormp-20120229_cal.xml	Edgar Link	unprocessable
ormp-20120229_def.xml	Edgar Link	unprocessable
ormp-20120229_lab.xml	Edgar Link	unprocessable
ormp-20120229_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zk1211274.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2012 Q2 Form 10-Q Financial Statement

#000117891312001000 Filed on April 04, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2012 Q2 Form 10-Q Financial Statement

#000117891312001000 Filed on April 04, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp